Showing results (201-210 of 237) with videos related to

Sort By:
Pageof 24
Haematologica|December 20, 2011
Discontinuation of imatinib in Japanese patients with chronic myeloid leukemiaNaoto Takahashi, Taiichi Kyo, Yasuhiro Maeda, et al.
Journal of Clinical and Experimental Hematopathology : JCEH|July 1, 2021
A multicenter, phase II study of R-THP-COP therapy for elderly patients with newly diagnosed, advanced-stage, indolent B-cell lymphomaKazunori Ohnishi, Ken Ohmachi, Kiyoshi Ando, et al.
International Journal of Hematology|January 12, 2011
Safety and efficacy of the terminal complement inhibitor eculizumab in Japanese patients with paroxysmal nocturnal hemoglobinuria: the AEGIS clinical trialYuzuru Kanakura, Kazuma Ohyashiki, Tsutomu Shichishima, et al.
Cancer Research|April 29, 2020
Overexpression of RUNX3 Represses RUNX1 to Drive Transformation of Myelodysplastic SyndromeTakako Yokomizo-Nakano, Sho Kubota, Jie Bai, et al.
American Journal of Hematology|December 23, 2014
Shorter halving time of BCR-ABL1 transcripts is a novel predictor for achievement of molecular responses in newly diagnosed chronic-phase chronic myeloid leukemia treated with dasatinib: Results of the D-first study of Kanto CML study groupNoriyoshi Iriyama, Shin Fujisawa, Chikashi Yoshida, et al.
Nature Communications|August 30, 2019
Author Correction: Lineage-specific RUNX2 super-enhancer activates MYC and promotes the development of blastic plasmacytoid dendritic cell neoplasmSho Kubota, Kenji Tokunaga, Tomohiro Umezu, et al.
Nature Communications|April 12, 2019
Lineage-specific RUNX2 super-enhancer activates MYC and promotes the development of blastic plasmacytoid dendritic cell neoplasmSho Kubota, Kenji Tokunaga, Tomohiro Umezu, et al.
American Journal of Hematology|June 24, 2015
Early cytotoxic lymphocyte expansion contributes to a deep molecular response to dasatinib in patients with newly diagnosed chronic myeloid leukemia in the chronic phase: results of the D-first studyNoriyoshi Iriyama, Shin Fujisawa, Chikashi Yoshida, et al.
Oncology Reports|September 27, 2016
Association of pleural effusion with an early molecular response in patients with newly diagnosed chronic-phase chronic myeloid leukemia receiving dasatinib: Results of a D-First studyMaki Hagihara, Noriyoshi Iriyama, Chikashi Yoshida, et al.
American Journal of Hematology|September 13, 2008
Multicenter prospective trial evaluating the tolerability of imatinib for Japanese patients with chronic myelogenous leukemia in the chronic phase: does body weight matter?Yoshinobu Kanda, Shinichiro Okamoto, Tetsuzo Tauchi, et al.
Pageof 24